CTOs on the Move


 
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pronai.com
  • 2150 – 885 West Georgia Street
    Vancouver, BC CAN V6C 3E8
  • Phone: 604.558.6536

Executives

Name Title Contact Details

Similar Companies

Arete Pharmacy Network

American Associated Pharmacies and H. D. Smith combined respective pharmacy services administrative organizations (PSAO) into a new PSAO, servicing more than 2,300 independent retail pharmacies across the United States. Arete Pharmacy Network will combine and succeed H. D. Smith`s Third Party Network and AAP`s United Drugs. Arete Pharmacy Network focuses on independents and community pharmacies, with a focus on managed care contracting and expanded tools and services, allows pharmacies to deliver quality care as a differentiator in their communities. Arete Pharmacy Network can help effectively manage the financial, quality and operational aspects of your pharmacy business.

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...

Kleo

Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.

Nexelis, a Q² Solutions

On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...